These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. All antipsychotics are equal, but some are more equal than others. Volavka J; Citrome L J Clin Psychiatry; 2009 Mar; 70(3):429-30. PubMed ID: 19317959 [No Abstract] [Full Text] [Related]
6. Characteristics and clinical changes during hospitalization in bipolar and psychotic disorder patients with versus without substance-use disorders. Vincenti A; Ventriglio A; Baldessarini RJ; Talamo A; Fitzmaurice G; Centorrino F Pharmacopsychiatry; 2010 Aug; 43(6):225-32. PubMed ID: 20652858 [TBL] [Abstract][Full Text] [Related]
8. A study of polypharmacy with second generation antipsychotics in patients with severe and persistent mental illness. Megna JL; Kunwar AR; Mahlotra K; Sauro MD; Devitt PJ; Rashid A J Psychiatr Pract; 2007 Mar; 13(2):129-37. PubMed ID: 17414692 [TBL] [Abstract][Full Text] [Related]
9. A treatment-relevant classification of psychotic disorders. McGorry P Aust N Z J Psychiatry; 1995 Dec; 29(4):555-8. PubMed ID: 8825814 [No Abstract] [Full Text] [Related]
10. Antipsychotic polypharmacy does not increase the risk for side effects. Ganesan S; Taylor R; Rabheru K; Forbes I; Dumontet J; Procyshyn RM Schizophr Res; 2008 Jan; 98(1-3):323-4. PubMed ID: 17950576 [No Abstract] [Full Text] [Related]
11. Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Essock SM; Schooler NR; Stroup TS; McEvoy JP; Rojas I; Jackson C; Covell NH; Am J Psychiatry; 2011 Jul; 168(7):702-8. PubMed ID: 21536693 [TBL] [Abstract][Full Text] [Related]
12. Fluvoxamine for psychosis in Alzheimer's disease. Levkovitz Y; Bloch Y; Kaplan D; Diskin A; Abramovitchi I J Nerv Ment Dis; 2001 Feb; 189(2):126-9. PubMed ID: 11225688 [No Abstract] [Full Text] [Related]
13. Algorithm for the treatment of acute psychotic episodes. Hayashida M; Nakane Y Psychiatry Clin Neurosci; 1999 Oct; 53 Suppl():S3-7. PubMed ID: 10560890 [TBL] [Abstract][Full Text] [Related]
14. Antipsychotic polypharmacy: do benefits justify the risks? Tapp AM; Wood AE; Kilzieh N; Kennedy A; Raskind MA Ann Pharmacother; 2005 Oct; 39(10):1759-60. PubMed ID: 16144885 [No Abstract] [Full Text] [Related]
15. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. McManus DQ; Arvanitis LA; Kowalcyk BB J Clin Psychiatry; 1999 May; 60(5):292-8. PubMed ID: 10362435 [TBL] [Abstract][Full Text] [Related]
17. Compliance and schizophrenia: the predictive potential of insight into illness, symptoms, and side effects. Kao YC; Liu YP Compr Psychiatry; 2010; 51(6):557-65. PubMed ID: 20965300 [TBL] [Abstract][Full Text] [Related]
18. Supersensitivity psychosis after tapering aripiprazole: a case report. Chang CC; Hsu WY; Chen SH Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):388-9. PubMed ID: 19166895 [No Abstract] [Full Text] [Related]
19. [Chronic and delusional psychoses]. Franck N Rev Prat; 2012 Jan; 62(1):115-22. PubMed ID: 22335082 [No Abstract] [Full Text] [Related]
20. Antipsychotic polypharmacy at admission predicts extended length of stay among state hospital inpatients. Lacasse JR Aust N Z J Psychiatry; 2014 Nov; 48(11):1065. PubMed ID: 24835210 [No Abstract] [Full Text] [Related] [Next] [New Search]